Article Details

Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Retrieved on: 2025-08-05 20:17:29

Tags for this article:

Click the tags to see associated articles and topics

Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update. View article details on hiswai:

Excerpt

SPY001 – a highly potent and selective investigational monoclonal antibody targeting α4β7, engineered with half-life extension technology and ...

Article found on: www.globenewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo